SEC Form 4 · accession 0001209191-18-058707
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — CFO
Period of report
Nov 13, 2018
Accepted (ET)
Nov 15, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 13, 2018 | M | 5,000 | $17.18 | A | 50,372 | D | |
| Common StockF1 | Nov 13, 2018 | M | 3,576 | $22.98 | A | 53,948 | D | |
| Common StockF2,F3,F4,F1 | Nov 13, 2018 | S | 2,817 | $78.2871 | D | 51,131 | D | |
| Common StockF2,F3,F5,F1 | Nov 13, 2018 | S | 600 | $79.2967 | D | 50,531 | D | |
| Common StockF2,F3,F6,F1 | Nov 13, 2018 | S | 1,083 | $80.3184 | D | 49,448 | D | |
| Common StockF2,F3,F7,F1 | Nov 13, 2018 | S | 500 | $81.602 | D | 48,948 | D | |
| Common StockF2,F3,F8,F1 | Nov 13, 2018 | S | 1,976 | $78.3428 | D | 46,972 | D | |
| Common StockF2,F3,F9,F1 | Nov 13, 2018 | S | 900 | $80.2302 | D | 46,072 | D | |
| Common StockF2,F3,F10,F1 | Nov 13, 2018 | S | 300 | $81.4567 | D | 45,772 | D | |
| Common StockF2,F3,F11,F1 | Nov 13, 2018 | S | 400 | $79.1975 | D | 45,372 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F12 | $17.18 | Nov 13, 2018 | M | 5,000 | D | — | Feb 18, 2020 | Common Stock | 5,000 | 41,471 | D |
| Employee Stock Option (right to buy)F13 | $22.98 | Nov 13, 2018 | M | 3,576 | D | — | Jan 27, 2021 | Common Stock | 3,576 | 56,424 | D |
Explanation of responses
- F1Includes an aggregate of 16,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F10Represents weighted average sale price. Actual sale prices ranged from $81.12 to $82.08.
- F11Represents weighted average sale price. Actual sale prices ranged from $78.93 to $79.62.
- F12The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
- F13The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plans adopted by the reporting person on June 4, 2018 and August 23, 2018.
- F3Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F4Represents weighted average sale price. Actual sale prices ranged from $77.87 to $78.71.
- F5Represents weighted average sale price. Actual sale prices ranged from $78.93 to $79.61.
- F6Represents weighted average sale price. Actual sale prices ranged from $79.93 to $80.70.
- F7Represents weighted average sale price. Actual sale prices ranged from $81.13 to $82.08.
- F8Represents weighted average sale price. Actual sale prices ranged from $77.90 to $78.80.
- F9Represents weighted average sale price. Actual sale prices ranged from $79.95 to $80.65.